Immunotherapy, especially immune checkpoint inhibition (CPI), has become a common treatment strategy for NSCLC. Many agents targeting PD-1 (e.g., nivolumab and pembrolizumab) and PD-L1 (e.g., atezolizumab) have been granted FDA approval for the treatment of NSCLC in patients expressing PD-L1 [1-3].
Extracellular matrix components, including stromal collagen, may prevent infiltration of tumors by T cells, resulting in poor CPI response to CPI [4].
To assess how collagen structure may influence clinical outcomes following CPI therapy, we developed an approach to extract and compute collagen fiber-based features from hematoxylin and eosin (H&E)-stained tumor sections, which we associate with CPI outcomes and lymphocyte infiltration in a NSCLC cohort
Conference
SITC 2024
View Poster